NEM:XETRNemetschek SE Analysis
Data as of 2026-06-08 - not real-time
$98.99
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Newmont (NEM) is trading at $98.99, well below its 20‑day ($109.60) and 50‑day ($111.62) SMAs and sitting near a technical support of $98.65, with a 14‑day RSI of 35.7 indicating oversold conditions. MACD remains bearish and the trend is neutral, but volume is increasing, suggesting potential accumulation.
Fundamentally, the company shows a 45.8% revenue growth year‑over‑year, ultra‑high operating margins (61%), a strong cash pile ($8.78 B) versus modest debt, and a low payout ratio (13%), making the dividend sustainable. The DCF fair value of $330.73 implies a 43% upside, while analysts have raised price targets to $145, labeling the stock as “most undervalued high‑quality.” Despite a high 30‑day volatility (~50%) and a beta above 1, the blend of growth and value attributes, coupled with a solid balance sheet, supports a bullish outlook.
Fundamentally, the company shows a 45.8% revenue growth year‑over‑year, ultra‑high operating margins (61%), a strong cash pile ($8.78 B) versus modest debt, and a low payout ratio (13%), making the dividend sustainable. The DCF fair value of $330.73 implies a 43% upside, while analysts have raised price targets to $145, labeling the stock as “most undervalued high‑quality.” Despite a high 30‑day volatility (~50%) and a beta above 1, the blend of growth and value attributes, coupled with a solid balance sheet, supports a bullish outlook.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price hovering at technical support
- Oversold RSI and bearish MACD
- Increasing volume indicating possible buying interest
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Strong revenue growth and high margins
- Analyst target uplift to $145 and undervaluation signal
- Favorable gold price outlook amid geopolitical uncertainty
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Robust cash generation and low dividend payout ratio
- Diversified global asset base reducing single‑country exposure
- Long‑term commodity demand supporting sustained earnings
Key Metrics & Analysis
Financial Health
Revenue Growth45.80%
Profit Margin33.87%
P/E Ratio12.8
ROE25.83%
ROA14.89%
Debt/Equity15.76
P/B Ratio3.0
Op. Cash Flow$12.1B
Free Cash Flow$9.8B
Technical Analysis
TrendNeutral
RSI35.7
Support$98.65
Resistance$121.26
MA 20$109.60
MA 50$111.62
MA 200$101.32
MACDBearish
VolumeIncreasing
Fear & Greed Index87.64
Valuation
Fair Value$330.73
Target Price$141.74
Upside/Downside43.19%
GradeUndervalued
TypeBlend
Dividend Yield1.04%
Risk Assessment
Beta1.36
Volatility49.83%
Sector RiskMedium
Reg. RiskMedium
Geo RiskHigh
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.